Camlin Fine Sciences Q1 FY27: revenue rises but losses widen sharply

Revenue Growth 20pctPat NegativeExceptional ItemEbitda Margin CompressionResults View source PDF Explain this filing

CAMLINFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-14.8%Reaction day

₹126.90

prior close

₹119.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-15.2% vs market

Specialty Chemicals peers, median of 93sector-0.3%-14.5% vs sector

On the reaction day the stock moved 15.2 pts less than Nifty Microcap 250 and 14.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.4

10m

-4.4

15m

-4.2

30m

-1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-14.8+0.4-15.2-0.3-14.5

Next day

-16.2+0.5-16.7-0.3-15.9

-18.1+0.6-18.7-0.2-17.8

-9.8+0.7-10.5-0.6-9.2

-13.7+1.1-14.8-0.7-13.0

-16.1+0.5-16.6-1.5-14.6

-13.9+1.3-15.2-0.9-13.0

15d

-19.2+0.5-19.7+0.2-19.4

-22.0-0.8-21.1-1.4-20.6

-29.8-0.9-28.8-2.5-27.3

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 93Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Camlin Fine Sciences Q1 FY27: consolidated revenue jumped 27.5% YoY to Rs 519.88 crore, but consolidated net loss widened sharply to Rs 329.66 crore from Rs 106.81 crore a year ago. Standalone revenue grew 16% to Rs 222.49 crore with a net loss of Rs 12.31 crore. The company booked an Rs 10.88 crore exceptional loss from an insurance shortfall at its Brazil blending unit. Operating EBITDA margins also compressed versus the prior year quarter.

Likely market impact

Mixed read for shareholders: top-line growth is strong on segment expansion, but profitability has worsened sharply with wider losses and margin pressure.